Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLC

E-ISSN： 1873-4286|20|24|3944-3957

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.20, Iss.24, 2014-05, pp. : 3944-3957

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Potential Application of Biliverdin Reductase and its Fragments to Modulate insulin/IGF-1/MAPK/PI3-K Signaling Pathways in Therapeutic Settings

Current Drug Targets, Vol. 11, Iss. 12, 2010-12 ,pp. : 1586-1594

Bentham Science Publishers

Access to resources Recommend Favorite

EGFR–PI3K–AKT–mTOR signaling in head and neck squamous cell carcinomas: attractive targets for molecular-oriented therapy

By Freudlsperger Christian Burnett Jeffrey R Friedman Jay A Kannabiran Vishnu R Chen Zhong Van Waes Carter

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 1, 2011-01 ,pp. : 63-74

Informa Healthcare

Access to resources Recommend Favorite

The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications

Current Cancer Drug Targets, Vol. 8, Iss. 3, 2008-05 ,pp. : 187-198

Bentham Science Publishers

Access to resources Recommend Favorite

The PI3K/Akt Pathway and Its Downstream Transcriptional Factors as Targets for Chemoprevention

Current Cancer Drug Targets, Vol. 7, Iss. 4, 2007-06 ,pp. : 305-316

Bentham Science Publishers

Access to resources Recommend Favorite

Salidroside attenuates myocardial ischemia–reperfusion injury via PI3K/Akt signaling pathway

By Xu Mao-Chun

Journal of Asian Natural Products Research, Vol. 15, Iss. 3, 2013-03 ,pp. : 244-252

Taylor & Francis Ltd

Access to resources Recommend Favorite